Dataset Information


Cerenkov Luminescence Imaging for Radiation Dose Calculation of a ??Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist.

ABSTRACT: (90)Y has been used to label various new therapeutic radiopharmaceuticals. However, measuring the radiation dose delivered by (90)Y is challenging because of the absence of suitable ? emissions and its low abundance of positron emissions. For the treatment of prostate cancer, radiolabeled gastrin-releasing peptide receptor (GRPr) antagonists have yielded promising results in mouse models. In this study, we evaluated whether Cerenkov luminescence imaging (CLI) could be used to determine radiation doses of a (90)Y-labeled GRPr antagonist in nude mice.Mice bearing subcutaneous prostate cancer xenografts were injected with 0.74-18.5 MBq of the (90)Y-labeled GRPr antagonist DOTA-AR and underwent in vivo and ex vivo CLI at 1-48 h after injection. After imaging, animals were sacrificed, their tumors and organs were harvested, and the activity concentration was measured by liquid scintillation counting. In a second set of experiments, Cerenkov photon counts for tumor and kidney on in vivo CLI were converted to activity concentrations using conversion factors determined from the first set of experiments.(90)Y-DOTA-AR concentration in the 3 tumor models ranged from 0.5% to 4.8% of the injected activity per gram at 1 h after injection and decreased to 0.05%-0.15 injected activity per gram by 48 h after injection. A positive correlation was found between tumor activity concentrations and in vivo CLI signal (r(2) = 0.94). A similar correlation was found for the renal activity concentration and in vivo Cerenkov luminescence (r(2) = 0.98). Other organs were not distinctly visualized on the in vivo images, but ex vivo CLI was also correlated with the radioactivity concentration (r(2) = 0.35-0.94). Using the time-activity curves from the second experiment, we calculated radiation doses to tumor and kidney of 0.33 ± 0.12 (range, 0.21-0.66) and 0.06 ± 0.01 (range, 0.05-0.08) Gy/MBq, respectively.CLI is a promising, low-cost modality to measure individual radiation doses of (90)Y-labeled compounds noninvasively. The use of Cerenkov imaging is expected to facilitate the development and comparison of (90)Y-labeled compounds for targeted radiotherapy.

SUBMITTER: Lohrmann C 

PROVIDER: S-EPMC4470706 | BioStudies | 2015-01-01

REPOSITORIES: biostudies

Similar Datasets

2014-01-01 | S-EPMC4199906 | BioStudies
2020-01-01 | S-EPMC7206480 | BioStudies
2016-01-01 | S-EPMC4805664 | BioStudies
1000-01-01 | S-EPMC5209642 | BioStudies
2010-01-01 | S-EPMC3068779 | BioStudies
2017-01-01 | S-EPMC5496795 | BioStudies
2016-01-01 | S-EPMC5037157 | BioStudies
2011-01-01 | S-EPMC3083828 | BioStudies
2015-01-01 | S-EPMC4543314 | BioStudies
1000-01-01 | S-EPMC5907375 | BioStudies